Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
On Friday, Alumis Inc (NASDAQ:ALMS) priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering.
週五，Alumis Inc（納斯達克股票代碼：ALMS）將其首次公開募股定價爲每股16美元，處於16美元至18美元區間的最低水平，通過1,313萬股股票發行籌集了2.1億美元。
Earlier, the company anticipated offering 17.65 million, raising $274 million and $315 million if the underwriters' over-allotment option is fully exercised.
此前，該公司預計 提供 1765萬美元，籌集2.74億美元，如果承銷商的超額配股權得到充分行使，則籌集了3.15億美元。
In addition, Alumis has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,968,750 shares.
此外，Alumis還授予承銷商30天的超額配股權，可以額外購買最多1,968,750股股票。
In addition to the shares being sold in the initial public offering, Alumis also announced that it has agreed to sell an additional 2.5 million shares in a concurrent private placement at $16.00 per share to AyurMaya Capital Management Fund, LP, its existing shareholder.
除了在首次公開募股中出售的股票外，Alumis還宣佈，它已同意以每股16.00美元的價格同時向其現有股東AyurMaya資本管理基金有限責任公司再出售250萬股股票。
The shares are expected to begin trading on the Nasdaq on June 28, 2024, under the symbol "ALMS."
這些股票預計將於2024年6月28日在納斯達克開始交易，股票代碼爲 “ALMS”。
Alumis is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.
Alumis是一家臨床階段的生物製藥公司，爲免疫介導的疾病開發口服療法。
Leveraging its proprietary precision data analytics platform, Alumis is building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies.
利用其專有的精密數據分析平台，Alumis正在建立分子管道，這些分子有可能解決單一療法或聯合療法等各種免疫介導疾病。
Alumis' most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of TYK2 that is currently being evaluated for moderate-to-severe plaque psoriasis and systemic lupus erythematosus.
Alumis 最先進的候選產品 ESK-001 是一種口服、高選擇性、小分子、TYK2 的變構抑制劑，目前正在對中度至重度斑塊狀銀屑病和系統性紅斑狼瘡進行評估。
In March, the company presented clinical data from a Phase 2 clinical trial of ESK-001 in patients with moderate-to-severe plaque psoriasis.
3月，該公司公佈了針對中度至重度斑塊狀牛皮癬患者的 ESK-001 二期臨床試驗的臨床數據。
Alumis plans to initiate Phase 3 trials of ESK-001 in moderate-to-severe plaque psoriasis in the second half of 2024.
Alumis 計劃在 2024 年下半年啓動 ESK-001 治療中度至重度斑塊狀牛皮癬的 3 期試驗。
Alumis is also developing A-005, a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, with potential application in multiple sclerosis and Parkinson's.
Alumis還在開發用於神經炎症和神經退行性疾病的CNS滲透劑變構TYK2抑制劑 A-005，有可能應用於多發性硬化症和帕金森氏症。
In April, the company initiated dosing in a Phase 1 trial of A-005 in healthy participants.
4月，該公司開始在健康參與者中服用 A-005 的 1 期試驗。
Beyond TYK2, Alumis' proprietary precision data analytics platform and drug discovery expertise have identified additional preclinical programs.
除TYK2外，Alumis專有的精密數據分析平台和藥物發現專業知識還確定了其他臨床前項目。
Price Action: ALMS shares were trading at $12.77 at the last check on Friday.
價格走勢：週五最後一次支票時，ALMS股票的交易價格爲12.77美元。
Photo via Shutterstock
照片來自 Shutterstock